(via TheNewswire)
Toronto, Ontario / TheNewswire / June 5, 2019 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have submitted for regulatory approvals in Canada, United States and Europe for their next-generation VMS+ 3.0 system.
"I am proud of the exemplary work performed by the regulatory affairs and design and development teams as we embark on this major milestone of submitting for regulatory approvals to the FDA, Health Canada and CE Notified Body for our VMS+ 3.0 system. We are now focused on our pre-launch marketing awareness strategy and global distribution plans," commented Dr. George Adams, Ventripoint CEO.
The VMS+ 3.0 system is designed to use Artificial Intelligence (AI) for volumetric measurements and ejection fractions for all 4 chambers of the heart, which are key indicators in cardiac diseases. It is a cost-effective diagnostic tool for measuring whole heart function utilizing standard 2D ultrasound. The system has a new patent-pending position sensor technology developed at Ventripoint to improve patient management and overall experience during the cardiac echo exam for pediatric and adult patients. An onscreen interactive guide has also been integrated to increase efficiency and ease of use for the clinician while performing imaging and analysis. The new compact and portable system can be set up within minutes providing a streamlined approach within the clinical environment where patient case load is continually increasing.
Until regulatory approvals have been received, the VMS+3.0 system is not commercially available but is available for investigational use.
About Ventripoint Diagnostics Ltd.
Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
For further information please contact:
Dr. George Adams, CEO, Telephone: (519) 803-6937
Email: gadams@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
Copyright (c) 2019 TheNewswire - All rights reserved.